Literature DB >> 30339899

Neutrophil to Lymphocyte Ratio as a Predictor of Outcomes after Amputation.

Willythssa S Pierre-Louis1, Jonathan Bath2, Sesank Mikkilineni3, Michael C Scott4, Michael Harlander-Locke5, Zachary Rasor6, Matthew Smeds3.   

Abstract

BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) has become a prognostic marker for proinflammatory states. It is associated with outcomes in many clinical processes including critical limb ischemia. We sought to identify predictors of amputation failure and mortality, in addition to the role of NLR in patients undergoing above-knee amputations (AKAs) or below-knee amputations (BKAs).
METHODS: All patients undergoing BKA or AKA between 2004 and 2014 at 3 institutions were identified and analyzed (n = 513). Patients were excluded if they did not have a complete blood count with differential within 7 days prior to their operations. Comparison groups were formed between patients requiring unplanned revision and those who did not, and additionally between survivors and nonsurvivors at 30 days postamputation. Patient demographics, intraoperative data, and postoperative courses were compared. A multinomial logistic regression model was created to further compare the groups.
RESULTS: Four hundred and ten patients were included for analysis, of which 142 (35%) required unplanned revision. Nearly 5% of patients (19/410) died within 30 days of the initial amputation. On univariate analysis, those requiring revision were more likely to be current smokers compared to former smokers (P = 0.004 and P = 0.021, respectively), have a lower ankle-brachial index (ABI) (P = 0.019), and have undergone a BKA (P < 0.001). Patients with congestive heart failure (CHF) were less likely to require a revision after an amputation (P = 0.007). Postoperative NLR was higher in patients requiring revision (9.9 vs. 7.0, P < 0.001) and both preoperative and postoperative NLRs were higher in those with 30-day mortality (21.0 vs. 7.0, P < 0.001; 19.4 vs. 7.5, P < 0.001). A multinomial logistic regression model identified CHF (P = 0.004), ABI (P = 0.041), and elevated body mass index (BMI, P = 0.045) as predictors of revision, while coronary artery disease (CAD, P = 0.031), CHF (P = 0.029), and postoperative NLR (P < 0.001) were predictive of 30-day mortality.
CONCLUSIONS: Postoperative elevated NLR, CAD, and CHF are predictors of 30-day mortality in patients undergoing major limb amputation, while CHF, elevated ABI, and high BMI are predictors of revision. This study suggests that NLR may have a role as a biomarker for poor outcomes in patients with underlying peripheral vascular disease and warrants further investigation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30339899     DOI: 10.1016/j.avsg.2018.10.002

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  An explainable machine learning model for predicting in-hospital amputation rate of patients with diabetic foot ulcer.

Authors:  Puguang Xie; Yuyao Li; Bo Deng; Chenzhen Du; Shunli Rui; Wu Deng; Min Wang; Johnson Boey; David G Armstrong; Yu Ma; Wuquan Deng
Journal:  Int Wound J       Date:  2021-09-14       Impact factor: 3.099

2.  Neutrophil-lymphocyte ratio predicts disease severity and outcome after lower extremity procedures.

Authors:  Jonathan Bath; Jamie B Smith; Robin L Kruse; Todd R Vogel
Journal:  J Vasc Surg       Date:  2019-12-25       Impact factor: 4.268

3.  Complex relationship between low albumin level and poor outcome after lower extremity procedures for peripheral artery disease.

Authors:  Jonathan Bath; Jamie B Smith; Jennifer Woodard; Robin L Kruse; Todd R Vogel
Journal:  J Vasc Surg       Date:  2020-05-26       Impact factor: 4.268

4.  Preoperative lymphopaenia, mortality, and morbidity after elective surgery: systematic review and meta-analysis.

Authors:  Johannes Schroth; Valentin Weber; Timothy F Jones; Ana Gutierrez Del Arroyo; Sian M Henson; Gareth L Ackland
Journal:  Br J Anaesth       Date:  2021-03-29       Impact factor: 11.719

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.